SOLIRENT
SOLIRENT has been active since 2009 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €58k and a net result of €4k. Equity is growing by ~7.8% per year across the filed fiscal years. Its solvency ranks better than 70% of 1465 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.6% (low).
| Equity | €58k |
| Net result | €4k |
| Better than sector | 70% |
| Active | 17 yrs |
Strong profile, led by stability.
All 5 axes are computed from data Checked has read.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 53.8% | 30.9% | |
| Net result | €4k | €6k | |
| Equity | €58k | €49k | |
| Gross operating margin | €8k | €34k | |
| Total assets | €109k | €189k |
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Deposit | micro schema | micro schema | micro schema | micro schema | micro schema |
| Revenue | - | - | - | - | - |
| EBITDA | €8k | €6k | - | €3k | €452 |
| Net profit | €4k | €4k | €4k | €4k | €-4k |
| Cash flow | €4k | €4k | - | €4k | €-3k |
| Staff costs | - | - | - | - | - |
| Income taxes | €1k | €1k | - | €0 | €3k |
| Dividends | - | - | - | - | - |
| Total assets | €109k | €107k | €113k | €104k | €102k |
| Equity | €58k | €55k | €51k | €47k | €43k |
| Debt | €50k | €53k | €62k | €57k | €59k |
| of which ≤ 1y | €50k | €53k | €62k | €57k | €59k |
| of which > 1y | - | - | - | - | - |
| Working capital | €55k | €51k | €49k | €45k | €39k |
| Employees (FTE) | - | - | - | - | - |
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Current ratio | 2.09 | 1.97 | 1.78 | 1.78 | 1.67 |
| Quick ratio | 2.09 | 1.97 | 1.78 | 1.78 | 1.67 |
| Working capital ratio | 50.5% | 47.3% | 43.0% | 42.9% | 38.8% |
| Solvency | 53.8% | 50.9% | 45.0% | 45.1% | 42.3% |
| Debt / equity | 0.86 | 0.97 | 1.22 | 1.22 | 1.36 |
| Long-term debt ratio | - | - | - | - | - |
| Interest coverage | 2.88 | 5.50 | - | 4.08 | 0.67 |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| ROA | 3.5% | 3.5% | 3.6% | 3.7% | -3.7% |
| ROE | 6.4% | 7.0% | 7.9% | 8.1% | -8.8% |
| EBITDA margin | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days inventory (DSI) | - | - | - | - | - |
Full annual accounts (23 line items)
| Line item | Code | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Balance sheet, Assets | ||||||
| TOTAL ASSETS | 20/58 | €109k | €107k | €113k | €104k | €102k |
| Fixed assets | 21/28 | €4k | €4k | €2k | €2k | €4k |
| Tangible fixed assets | 22/27 | €1k | €2k | - | €0 | €1k |
| Financial fixed assets | 28 | €2k | €2k | €2k | €2k | €2k |
| Current assets | 29/58 | €105k | €103k | €111k | €101k | €98k |
| Amounts receivable within one year | 40/41 | €92k | €96k | €104k | €88k | €94k |
| Cash & bank | 54/58 | €13k | €7k | €6k | €13k | €4k |
| Balance sheet, Equity & liabilities | ||||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €109k | €107k | €113k | €104k | €102k |
| Equity | 10/15 | €58k | €55k | €51k | €47k | €43k |
| Contributions / capital | 10/11 | €25k | €25k | €25k | €25k | €25k |
| Reserves | 13 | €33k | €2k | €2k | €2k | €2k |
| Accumulated profits (losses) | 14 | €0 | €28k | €24k | €20k | €16k |
| Amounts payable | 17/49 | €50k | €53k | €62k | €57k | €59k |
| Amounts payable within one year | 42/48 | €50k | €53k | €62k | €57k | €59k |
| Trade debts payable within one year | 44 | €10k | €14k | €15k | €10k | €10k |
| Income statement | ||||||
| Gross operating margin | 9900 | €8k | €7k | €5k | €5k | €3k |
| Operating result | 9901 | €7k | €6k | €4k | €3k | €122 |
| Financial income | 75 | €499 | €0 | €0 | €717 | €16 |
| Financial charges | 65 | €3k | €1k | €440 | €738 | €677 |
| Result before taxes | 9903 | €5k | €5k | €4k | €4k | €-539 |
| Income taxes | 67/77 | €1k | €1k | - | €0 | €3k |
| Net result for the period | 9904 | €4k | €4k | €4k | €4k | €-4k |
| Result to be appropriated | 9905 | €4k | €4k | €4k | €4k | €-4k |
-
VAN GILS JuulDirectorState Gazette act 23456832 (13-12-2023)Current13-12-2023 → present
2 events
- 13-12-2023 Resigned· Manager
- 13-12-2023 Appointed· Director
| NACE primary | Renting and leasing of other machinery, equipment and tangible goods(77399) |
| Legal form | Private limited company(610) |
| Incorporation | 15-06-2009 |
| Status | Active |
| Postal code | 2960 |
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11043D0765/00M002 | Flanders | 903 m² | 1 · 788 m² | 11.6 m · 2 fl. |
We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
13-12-2023 1 director appointed, 1 resigning
- VAN GILS Juul, Bestuurder
- VAN GILS Juul, Zaakvoerder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "zaakvoerder",
"person": {
"rrn": null,
"name": "VAN GILS Juul",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "VAN GILS Juul",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0812.280.869",
"name_full": "SOLIRENT"
}
}| Legal nameNL | SOLIRENT |